Guardant Health stock

GH · NASDAQ · USD

Compare Guardant Health
$145.02Change from previous close: −4.40%Absolute change: −$6.68

Close · November 16, 2026

Price history

+50.31% over the period

1 year: from $96.48 (November 17, 2025) to $145.02 (November 16, 2026), +50.31%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$145.02
October 30, 2026$178.80
September 30, 2026$178.36
August 31, 2026$159.02
July 31, 2026$161.99
June 30, 2026$150.03
May 29, 2026$129.69
April 30, 2026$87.08
March 31, 2026$92.37
February 27, 2026$93.90
January 30, 2026$114.04
December 31, 2025$102.14
November 28, 2025$108.42
November 17, 2025$96.48

At a glance

  • The company

    Precision oncology company providing blood and tissue tests for cancer detection, profiling and research

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.29 (estimate -$0.75)

TickerLandia's take on Guardant Health

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$74.55
52-wk high$191.05

−24.09% from the 52-week high

Analysts · 26 analysts

Average target$200.76+38.44% vs. price

Buy 25 · Hold 0 · Sell 1 · Strong buy

TickerLandia Fingerprint: Guardant Health

Compared with similar companies: very low earnings stability.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

How Guardant Health is valued

Compared with 11 similar companies

Guardant Health's metrics compared with similar companies
MetricGuardant HealthPosition in the groupBand
Operating margin-39.4%Low
ROE171.6%High
Debt/equity-7.61Low
Net margin-37.9%Low
Price/sales16.0High

Grey band: the middle half of the group; tick: the median; dot: Guardant Health. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$334.98M

Latest quarter · Q2 2026

Net income

-$120.14M

Latest quarter · Q2 2026

Quarterly net margin

-35.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$20.52B
EPS
-$3.68
Volume
1.29M
Daily trading
€336.2M
Dividend yield
0.00%

How Guardant Health is changing

All results
  • Revenue grew 27.9% a year on average over the last 5 years

  • Operating margin rose from −121.1% to −44.4%

  • Shares outstanding up 28.6% in 5 years

Returns

Guardant Health returns

$1,000 invested in Guardant Health 5 years ago, on November 16, 2021, would be worth $1,378 today: +37.81% in total, +6.63% per year. This is the price return only: dividends are excluded.

PeriodGuardant HealthS&P 500$1,000 becomes
1 month−8.56%−3.12%$914
6 months+52.78%+2.07%$1,528
Year to date+41.98%+10.46%$1,420
1 year+50.31%+13.33%$1,503
3 years+548.57%+67.73%$6,486
5 years+37.81%+60.86%$1,378

Over the last 6 months it has done better than 88% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Guardant Health: technical analysis

Guardant Health shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 22.5% below its all-time closing high ($187.22, October 5, 2026).

Trend
No clear trend
RSI (14 sessions)
35
Between 30 and 70
vs 200-session average
+9.09%

Support and resistance

Price areas where Guardant Health has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$184.77+27.41%2 touches, last on October 28, 2026
  2. Resistance$173.94+19.94%4 touches, last on August 26, 2026
  3. Resistance$154.16+6.30%4 touches, last on October 19, 2026
  4. Last price$145.02
  5. Support$135.23−6.75%3 touches, last on November 6, 2026
  6. Support$122.83−15.30%3 touches, last on June 17, 2026
  7. Support$114.53−21.02%4 touches, last on February 20, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.35
Volatility (60 sessions, annualised)
50.1%
Largest fall in the last year
−32.98%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Guardant Health: seasonality

Average monthly price change over 8 years

+7.1%Jan+3.4%Feb−2.3%Mar−2.3%Apr+11.8%May+9.1%Jun+5.5%Jul+7.1%Aug−4.2%Sep+2.7%Oct+13.0%Nov−6.6%Dec

Over the last 8 years, the strongest month for Guardant Health has been November: +13.04% on average, positive in 6 years out of 8. The weakest has been December: −6.65% on average, positive in 4 years out of 8.

Show chart data
MonthAverageMedianPositive years
January+7.11%+9.48%5 of 8
February+3.42%−5.03%2 of 8
March−2.28%+0.04%4 of 8
April−2.26%−4.74%3 of 8
May+11.84%+17.40%5 of 8
June+9.13%+9.43%6 of 8
July+5.50%+8.42%6 of 8
August+7.07%−0.03%4 of 8
September−4.24%−4.55%3 of 8
October+2.69%−4.60%3 of 8
November+13.04%+9.24%6 of 8
December−6.65%−2.12%4 of 8

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Guardant Health and its competitors

Founded in 2011 and based in Palo Alto, California, the company focuses on precision oncology, analyzing DNA from blood and tumor samples to support cancer care and research. Its Guardant360 tests profile tumors for clinicians, the Guardant Reveal test detects cancer through circulating tumor DNA, and the Shield blood test screens adults for colorectal cancer. For drug developers and biopharmaceutical customers it offers the GuardantINFINITY and GuardantOMNI assays, the GuardantConnect software, and development services that range from companion diagnostics to clinical study support and kit delivery.

Headquarters
Palo Alto, United States
Employees
2,490
Founded
2011
Chief executive
Dr. Helmy Eltoukhy Ph.D.
Guardant Health and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Guardant HealthGH$20.52B-39.4%—+52.78%
Medpace HoldingsMEDP$19.12B21.4%38.0+57.36%
RevvityRVTY$17.84B16.3%70.5+59.49%
Charles River Laboratories InternationalCRL$16.19B14.3%367.4+123.10%
Quest DiagnosticsDGX$28.56B14.9%25.9+40.23%
ICON PublicICLR$14.58B2.7%77.9+63.31%

Same industry or related industries, similar size. Compare Guardant Health with its competitors · Full profile